Profound Medical Corp. (PROF): Price and Financial Metrics
GET POWR RATINGS... FREE!
PROF POWR Grades
- PROF scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.12% of US stocks.
- The strongest trend for PROF is in Quality, which has been heading up over the past 179 days.
- PROF's current lowest rank is in the Value metric (where it is better than 10.9% of US stocks).
PROF Stock Summary
- The ratio of debt to operating expenses for PROFOUND MEDICAL CORP is higher than it is for about only 8.1% of US stocks.
- PROF's price/sales ratio is 20.77; that's higher than the P/S ratio of 94.4% of US stocks.
- PROF's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 7.26% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to PROFOUND MEDICAL CORP are LGVN, VLD, IVAC, CLXT, and MNTS.
- PROF's SEC filings can be seen here. And to visit PROFOUND MEDICAL CORP's official web site, go to www.profoundmedical.com.
PROF Price Target
For more insight on analysts targets of PROF, see our PROF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.60 | Average Broker Recommendation | 1.3 (Strong Buy) |
PROF Stock Price Chart Interactive Chart >
PROF Price/Volume Stats
| Current price | $5.28 | 52-week high | $12.27 |
| Prev. close | $4.95 | 52-week low | $3.10 |
| Day low | $4.92 | Volume | 123,400 |
| Day high | $5.32 | Avg. volume | 51,577 |
| 50-day MA | $4.22 | Dividend yield | N/A |
| 200-day MA | $6.95 | Market Cap | 110.23M |
Profound Medical Corp. (PROF) Company Bio
Profound Medical Corp. operates as a medical device company. The Company develops and commercializes technology for the treatment of localized prostate cancer. Profound Medical offers its services worldwide.
Latest PROF News From Around the Web
Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Profound Medical to Present at the 2022 Jefferies London Healthcare ConferenceTORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT. The presentation will be broadcast l |
Profound Medical Announces Third Quarter 2022 Financial ResultsTORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Rep |
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to FollowTORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022. |
Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate CancerTORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that updated results from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study were presented for the first time this past weekend, on Saturday, September 24, 2022, by Laurence Klotz, M.D., FRCSC, CM, Professor of Surge |
Profound Medical Announces Changes to its Commercial Organization to Support Continued GrowthTORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced changes to its management team and structure designed to further position the Company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed Chief Commercial Officer – U.S. a |
PROF Price Returns
| 1-mo | 34.69% |
| 3-mo | -19.02% |
| 6-mo | -43.71% |
| 1-year | -52.65% |
| 3-year | -34.41% |
| 5-year | N/A |
| YTD | -52.98% |
| 2021 | -45.38% |
| 2020 | 87.76% |
| 2019 | 160.71% |
| 2018 | -35.64% |
| 2017 | N/A |
Loading social stream, please wait...